Gynecologic Oncology: Clinical and Translational Research
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 November 2024 | Viewed by 180
Special Issue Editors
Interests: phase I study; translational research; drug development; targeted therapy
Special Issues, Collections and Topics in MDPI journals
Interests: phase I study; translational research; drug development; targeted therapy
Special Issue Information
Dear Colleagues,
Over the last few decades, the treatment of gynecological cancers has dramatically changed due to the introduction of immunotherapy in endometrial and cervical cancer and target therapies in ovarian cancer, with more and more improvements expected to come (e.g., antibody–drug conjugates, as well as new powerful combinations). This has led to modification of the treatment algorithm, as well as the use of new molecular tests and a more and more personalized approach. In this issue, we want to provide evidence on the management of these malignancies in the era of personalized medicine with a focus on real-world data on effectiveness and toxicity. Moreover, we will welcome translational studies regarding not only prognostic and predictive biomarkers, but also mechanisms of resistance to the current treatments and possible approaches to overcome them.
Dr. Gennaro Daniele
Dr. Pasquale Lombardi
Dr. Gaia Giannone
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- gynecological cancer
- ovarian cancer
- translational research
- effectiveness
- toxicity
- immunotherapy
- PARP inhibitors
